Girding against Keytruda cliff, Merck splits oncology into standalone business unit

The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. | The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its oncology megablockbuster, the company is honing its focus on new and upcoming medicines by splitting its core pharmaceutical business in two.Read More